NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
TOP NEWS
»24/09/2009 [Industry news]
China Biologic Products Enters into a Strategic Research and Development Agreement with IBT of CAMS

China Biologic Products, Inc. one of the leading plasma-based pharmaceutical companies in China , today announced that on September 11, 2009, the Company entered into a strategic research and development agreement with the Institute of Blood Transfusion based in Chengdu, Sichuan Province, to strengthen the Company\'s research and development capabilities and manufacturing processes.

 
China Biologic Products, Inc. one of the leading plasma-based pharmaceutical companies in China , today announced that on September 11, 2009, the Company entered into a strategic research and development agreement with the Institute of Blood Transfusion based in Chengdu, Sichuan Province, to strengthen the Company\'s research and development capabilities and manufacturing processes. IBT is a division of the Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS). The IBT is a leading research institute in China, specializing in a variety of plasma-based research including research on the safety of blood transfusions, blood immunology, transfusion disposable materials, blood biochemistry and molecular biology. China Biologic\'s collaboration with IBT will include the use of IBT\'s technology to enhance safe and efficient plasma collection, and increase the range of plasma-derivative products that can be manufactured by the Company. The agreement also entitles China Biologic to utilize IBT\'s platform technologies, including its recombinant protein therapeutics, monoclonal antibody technology and diagnostics. China Biologic will collaborate by providing partial funding, plasma, the use of its manufacturing facilities, and access to its research and development resources. IBT will provide specialised training and education to China Biologic\'s research staff, and will procure additional funding from national and provincial funding bodies. In addition, China Biologic is entitled to the priority purchase rights to commercialise any new technologies or products that result from the collaboration. \"We are committed to being a technology leader in the area of plasma-based pharmaceuticals and we constantly seek to improve our collection and manufacturing processes,\" commented Mr. Chao Ming Zhao, CEO of China Biologic Products. \"China\'s plasma-based industry is underpenetrated, partially due to the scarcity of investment in the research and development of new products, as compared to similar investment in more developed countries. We are pleased to enter into the research and development agreement with IBT, which we believe will enable us to leverage IBT\'s advanced scientific resources to accelerate our development of new products and improve the efficiency of our operations.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.